Rapamycin: a transplant drug with a longevity following

Using an FDA-approved sirolimus product for longevity is off-label: it is approved to protect transplanted kidneys and to treat a rare lung disease, not to slow aging. A compounded rapamycin product is unapproved. Its following comes from a 2009 mouse study that made headlines and from a handful of small human trials since ^[8]. That gap between the mouse data and the human data is the most useful thing to understand before you ask a prescriber about it.

Rapamycin and sirolimus are the same drug

Rapamycin is the original name and sirolimus the generic name of one molecule. The label says it plainly: “sirolimus (also known as rapamycin)” ^[1]. It’s sold as the brand Rapamune and as generic sirolimus tablets.

It was first found as a compound made by a bacterium, and a 2017 review traces its discovery and its later uses, from fighting fungi to suppressing the immune system ^[14]. You won’t get rapamycin from food or a supplement; it’s a prescription drug made by fermentation.

What the FDA approved it for, and what it didn’t

FDA approved Rapamune oral solution in September 1999 and tablets in August 2000 ^{[4] [5]}. In May 2015 it added lymphangioleiomyomatosis (LAM), a rare lung disease ^[6]. Two other sirolimus products treat rare conditions: Hyftor, a topical gel for facial angiofibroma from tuberous sclerosis in people 6 and older ^[2], and Fyarro, an IV form for a rare tumor called PEComa, first approved in 2021 ^[3].

No FDA approval covers aging, longevity or “healthspan.” A doctor may still prescribe an approved drug for another use; FDA calls this unapproved or “off-label” use, and it means FDA hasn’t reviewed the benefits and risks for that purpose ^[7].

How it works: it blocks mTOR, a growth switch

Rapamycin binds a protein inside cells called FKBP-12, and that pair then “binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase,” in the label’s words ^[1]. In transplant patients, that slows the immune cells that would attack a new kidney.

mTOR is a growth-signaling hub. When it’s switched on, cells build and divide; when it’s turned down, they shift toward maintenance and recycling, a process called autophagy. That’s the reason researchers became interested in rapamycin for aging: dialing back mTOR extends lifespan in yeast, worms and flies ^[8]. Turning down the immune system is also exactly why the drug carries its main risks.

Is rapamycin a senolytic? It is not FDA-approved as a senolytic, and the cited skin trial does not establish that it clears senescent cells. Senolytics are drugs meant to clear out senescent, or “zombie,” cells. The cited small human skin study of topical rapamycin found less p16INK4A, a marker of senescent cells, but it didn’t measure whether those cells were removed ^[12].

How it affects the immune system

At transplant doses, rapamycin is meant to weaken the immune system. The label says it blocks T-cell activation and multiplication, and “also inhibits antibody production” ^[1]. That protects a new kidney. Those actions create infection and vaccination concerns; the effect of a particular intermittent regimen in healthy adults is not established by the transplant label. The label advises avoiding live vaccines.

The longevity idea is different: a small, intermittent dose might nudge mTOR without the full immune hit. The everolimus studies in older adults are the main human support for that idea, since flu-vaccine response improved rather than fell ^[9]. It remains a hypothesis. The cited sirolimus trials do not settle the long-term benefits and harms of that approach.

The mouse study that started it: 9% to 14% longer lives

In 2009, a National Institute on Aging testing program fed rapamycin to genetically mixed mice starting at 600 days old, which is late middle age for a mouse. Measured at the age when 90% of the mice had died, it extended lifespan by 14% in females and 9% in males, and the result held at three separate test sites ^[8].

The authors called it the first drug shown to extend lifespan in both male and female mammals. It’s still a mouse study. Mice in a lab don’t face what people face, the doses don’t translate directly, and the cited human trials do not establish the same effect.

What human studies show, and don’t

The cited human trials do not establish that rapamycin extends lifespan. The human evidence is small, short and mostly about immune function or body measures. Several of the most-cited studies didn’t even use sirolimus.

There’s a practical reason for that. Establishing a longevity benefit requires appropriately designed human trials with meaningful clinical outcomes and sufficient follow-up. So researchers measure stand-ins instead: vaccine response, infection rates, body fat, lean mass, skin markers. Each stand-in tells you something about how the drug acts. None of them tells you whether you’ll live longer. Keep that in mind whenever a program says rapamycin “slows aging”: the honest version is that it changes some markers in small studies, and nobody yet knows what that adds up to over a lifetime.

The immune studies. Mannick and colleagues gave older volunteers everolimus (RAD001), a close relative of sirolimus. Their flu-vaccine response improved by about 20% at doses that were relatively well tolerated ^[9]. A 2018 follow-up with 264 older adults combined everolimus with a second mTOR blocker, BEZ235, for six weeks; reported infections over the next year fell ^[10]. Neither study used rapamycin itself.

PEARL. This is the trial longevity programs point to most often. Healthy, aging adults took placebo or 5 mg or 10 mg of compounded rapamycin once a week for 48 weeks. Its primary outcome, visceral fat, did not change (p = 0.942). Women on 10 mg gained lean tissue and reported less pain, and some people on 5 mg reported better well-being, but those were secondary findings that need repeating ^[11]. Several of PEARL’s authors are employees and shareholders of AgelessRx, a telehealth company that sells rapamycin. Read its upbeat conclusion with that in mind.

Topical rapamycin. In a small skin study, 36 adults over 40 were enrolled and 19 didn’t finish. Those who did showed lower p16INK4A and higher collagen VII, and some looked better in photos ^[12]. The approved topical product, Hyftor, is for a different condition entirely, facial angiofibroma in tuberous sclerosis, where a 2024 review found it worked well in trials ^[13]. Compounded skin-aging creams are unapproved products, distinct from using an approved gel for an unapproved purpose.

Side effects, and who should not take it

Rapamycin suppresses the immune system, and its label leads with that. The boxed warning reads: “increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression” ^[1].

The most common side effects in the LAM trial, in 20% or more of people, were mouth sores (stomatitis), diarrhea, stomach pain, nausea, sore throat and colds, acne, chest pain, swelling in the legs, headache, dizziness, muscle aches and high cholesterol ^[1]. The label also warns about raised blood fats, slow wound healing, lung inflammation, skin cancer, harm to a fetus and lower male fertility. In kidney-transplant studies, the most common reactions, in 30% or more, included leg swelling, high triglycerides and cholesterol, high blood pressure, a rise in creatinine (a kidney marker), constipation, stomach pain, diarrhea, headache and fever ^[1]. Live vaccines should be avoided. The label tells prescribers to avoid strong CYP3A4 or P-gp blockers, such as ketoconazole, voriconazole, itraconazole, erythromycin and clarithromycin, and strong inducers such as rifampin. Many other drugs change rapamycin levels; the label says grapefruit juice “must not be taken with” it.

Who should be especially careful? Anyone with an active infection, a history of cancer, a planned surgery or wound that needs to heal, or a pregnancy plan. Anyone taking drugs that interact with it should also talk this through with their prescriber. Labs before and during treatment, such as blood counts, kidney function and cholesterol, are how a prescriber watches for trouble.

How long rapamycin stays in the body: a half-life of about 2.5 days

Rapamycin clears slowly. In stable kidney-transplant patients on daily doses, the label puts its mean terminal half-life at about 62 hours, give or take 16 ^[1]. That’s roughly two and a half days for half the drug to leave the blood. Most of it leaves through the gut, not the kidneys. The long half-life is part of why some longevity programs use once-a-week schedules, but the cited trials do not establish a schedule for extending human lifespan.

Is there a right age to start? No one has established one

No FDA-approved label sets a starting age for longevity use, and the cited trials do not establish one. The transplant label covers patients 13 and older, but that’s for a transplant, not for aging ^[1]. PEARL enrolled healthy, “normative-aging” adults and didn’t test whether starting earlier or later matters ^[11]. The mouse study started treatment late in life and still saw a lifespan gain, which says something about mice, not about when a person should begin ^[8].

If a program names an ideal starting age, ask what study it comes from. The cited trials do not establish an ideal starting age.

Getting it, and what it costs

You need a prescription. Some telehealth programs prescribe rapamycin off-label for longevity, usually after an intake form and lab work; a primary-care doctor can also prescribe generic sirolimus. Confirm the medication, monitoring and clinical-service charges for the actual prescribed product.

Also offered by (no standing monthly price published): HealthRx.

The table is short because few programs prescribe rapamycin. HealthRx and AgelessRx both bill monthly. Whether prices include labs, follow-ups and the drug itself differs, so compare the whole monthly cost. The legal side of buying it, and what to watch for online, is in can you buy rapamycin legally. Programs side by side are on the longevity prescription programs scorecard.

What a program shouldn’t do is promise a longer life. The cited trials do not establish that benefit. A careful one will tell you it’s off-label, check your labs, and stop the drug if side effects show up.

Compounded rapamycin vs generic sirolimus: not the same thing

Generic sirolimus is an FDA-approved product. FDA approves a generic only after it shows it’s equivalent to the brand. A compounded rapamycin capsule is different: “Compounded drugs are not FDA-approved,” and FDA “does not verify the safety, effectiveness or quality of compounded drugs before they are marketed” ^[16].

That matters because PEARL used compounded rapamycin ^[11], and some longevity programs sell compounded versions while others fill generic tablets. FDA also says compounded drugs “should only be used in patients whose medical needs cannot be met by an FDA-approved drug” ^[16]. Since generic sirolimus tablets exist, ask your program which one you’re getting and why. The answer distinguishes an FDA-approved product from an unapproved compounded preparation; it does not establish approval for aging.

What careful off-label prescribing looks like

An off-label prescription puts more of the judgment on your prescriber, because FDA hasn’t weighed the benefits and risks for that use ^[7]. In practice, that means a few things you can check for yourself.

• A real intake: your medical history, current medicines and any cancer, infection or surgery plans.
• Baseline labs before the first dose, and repeat labs on a schedule.
• A clear statement that this is off-label and unproven for longevity.
• A plan to pause before surgery or during an infection.
• Someone who answers questions after the medicine ships.

Rapamycin vs metformin: two off-label longevity drugs, different evidence

Metformin is the other generic drug people take off-label for aging. It treats type 2 diabetes, and the planned TAME trial was designed to test whether it delays age-related disease ^[15]. Rapamycin works on mTOR directly and suppresses the immune system; metformin works mostly on blood sugar and carries a different boxed warning, lactic acidosis. The cited studies do not establish that either extends human lifespan. The metformin evidence is in metformin for longevity, and the label facts are on the metformin page.

If your longevity interest is mostly about weight and metabolic health, approved GLP-1 drugs have larger trials for their labeled conditions; those findings do not establish a general longevity indication. See semaglutide for the approved formulations and their clinical context.

Questions to ask a prescriber about rapamycin

1. What do you expect this to do for me, and how will we measure it?
2. Which labs do you want before I start, and how often after?
3. Is this compounded rapamycin or generic sirolimus, and from which pharmacy?
4. What should I do if I get mouth sores, an infection or a wound that won’t heal?
5. Which of my other medicines or supplements interact with it?
6. When would you tell me to stop?